small nuclear ribonucleoprotein polypeptides B and B1Genealiases: CCMS · COD · SNRPB1 · Sm-B/B' · SmB/B' · SmB/SmB'
Q-omics provides the consensus-scored SNRPB profile across patient tissues and cancer cell-line models. SNRPB expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SNRPB is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SNRPB RNA expression shows 19,112 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where SNRPB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPB survival associations across molecular data types. SNRPB RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPB RNA expression–survival associations across cancer types. High SNRPB expression shows unfavorable associations in KIRP, UVM, MESO, LIHC, ACC and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SNRPB RNA expression.
This table summarizes SNRPB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SNRPB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPB shows higher tumor expression in HNSC, KIRC, BLCA, COAD, KIRP and LIHC. The HNSC box plot shows higher SNRPB RNA expression in tumor versus normal tissue (log2 FC = +1.405, t-test p < 0.001).
This table shows molecular features associated with SNRPB in patient tissues and cancer cell lines. In patient samples, SNRPB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNRPB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
